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Abstract
Background: To finish an endurance race, athletes perform a vigorous effort that induces the release of cardiac damage markers. There are sev-
eral factors that can affect the total number of these markers, so the aim of this review was to analyze the effect of endurance running races on
cardiac damage markers and to identify the factors that modify the levels of segregation of these cardiac damage markers.
Methods: A systematic search of PubMed, Web of Science, and the Cochrane Library databases was performed. This analysis included studies
where the acute effects of running races on cardiac damage markers (troponin I and troponin T) were analyzed, assessing the levels of these
markers before and after the races.
Results: The effects of running races on troponin I (mean difference = 0.0381 ng/mL) and troponin T (mean difference = 0.0256 ng/mL) levels
were significant. The ages (R2 = 14.4%, p = 0.033) and body mass indexes (R2 = 14.5%, p = 0.045) of the athletes had a significant interaction
with troponin I. In addition, gender, mean speed, time to finish the race, and type of race can affect the level of cardiac damage markers.
Conclusion: Endurance running races induce the release of cardiac-damage markers that remain elevated for at least 24 h after the races. In addi-
tion, young male athletes with high body mass indexes who perform races combining long duration and moderate intensity (i.e., marathons)
release the highest levels of cardiac damage markers. Physicians should take into consideration these results in the diagnosis and treatment of
patients admitted to the hospital days after finishing endurance running races.
Keywords: Endurance races; Troponin I; Troponin T; Ultra-endurance1. Introduction
Light and moderate aerobic exercise has been promoted as
a healthful physical activity (PA) associated with multiple
benefits and a longer life expectancy. Although the contro-
versy about its optimal dose continues, the scientific evidence
suggests that the presence of any kind or level of PA is much
better for an individual than a sedentary lifestyle.1,2 Likewise,Peer review under the responsibility of Shanghai University of Sport.
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running on cardiac damage markers in amateur runners: a systematic review, meta-aaerobic exercise generates positive effects on the cardiovascu-
lar system,3 reducing, for example, events of coronary heart
disease.4 In fact, a longitudinal study with a large sample
showed reductions in cardiovascular disease mortality (45%)
and an increase in cardiovascular disease life expectancy (4.1
years) for runners compared to nonrunners.5 Moreover, Arem
et al.6 reported that performing PA  10 times the minimum
recommended by the official guidelines (75 metabolic
equivalent task-h/week) is not associated with an increased
mortality risk, but at the same time, this level of PA has a
greater risk of all-cause mortality compared with moderate
levels of PA.uez A, Manonelles P, Ramos-Campo DJ. Effects of medium- and long-distance
nalysis, and metaregression. J Sport Health Sci 2021;10:192200.
Damage markers and long distance running 193Accordingly, endurance training for higher cardiorespira-
tory fitness levels (measured during cardiopulmonary exercise
testing and expressed as maximum rate of oxygen consump-
tion (VO2max)) is associated with numerous health benefits
(e.g., longer lifespan, better quality of life, lower declination
of functional and aerobic capacity, and reduced risks of all-
cause and cardiovascular mortality).7,8
Partly for these reasons, endurance and ultraendurance
races, as PA practices, have become very popular, and the
number of participants has increased in recent times.9
However, extreme and competitive endurance events
involve a considerably higher level of exercise than is rec-
ommended by the official guidelines, without being associ-
ated with the benefits that moderate PA could lead to in
health status.10
Short-, medium-, and long-distance running races differ
in terms of volume and intensity, can involve vigorous phys-
ical effort, and can generate changes in blood biomarkers
caused by physiopathological events.11 This type of PA can
keep certain biomarkers elevated for days and damage an
athlete’s health due to the appearance of rhabdomyolysis,12
acute muscle damage and inflammation,13 or cardiac
damage.14 In addition, it may increase the risk of the acute
and transient effect of sudden cardiac death and acute myo-
cardial infarction in susceptible populations.4
Several studies have investigated acute changes in bio-
markers related to heart damage.14,15 Troponin I (cTnI) and
troponin T (cTnT) are highly specific “cardiac troponin”
proteins (cTns) involved in myocardial cell damage and are
key factors in the diagnosis of acute coronary syndromes
and myocardial necrosis.16 Stress situations may lead to a
cTns increase in professional and recreational athletes with-
out coronary disease, but the prevalence,17 mechanisms,
and clinical importance of exercise-induced cTns release
are still not fully understood.
However, recent studies have shown that cTns increase
after aerobic exercise,14,15 in which high cardiac output, ele-
vated heart rate, and increased blood pressure are required for
several hours, resulting in greater cardiac work through myo-
cardial work.17 Some of the factors that can modify cardiac
injury to a greater or lesser extent after this type of event may
be associated with the characteristics of participants and run-
ning events. There is an individual variability in the cTnT
response to acute exercise, depending on several potentially
moderating factors (age, body mass, and VO2max).
18
However, from a clinical point of view, health care staff
must be aware of what may cause the elevation of cTns and
which factors associated with the race and the person may
have generated an increase in those markers after the end of
long-distance running in an endurance event on foot.
Therefore, the purposes of the present systematic review
and meta-analysis were to analyze: (1) the impact of
medium- and long-distance running on the heart proteins,
cTnI and cTnT, 24 h after the end of the race and (2) the
moderating factors related to the race and to the runners’
characteristics that could generate an increase in the final
levels of cTnI and cTnT.2. Methods
2.1. Study design
The methodological process was based on the recommenda-
tions indicated by the Preferred Reporting Items for System-
atic Review and Meta-Analysis (PRISMA) declaration.19 The
study was preregistered in the PROSPERO with the following
registered number: CRD42019129591.
2.2. Data sources and search profile
A comprehensive literature search was performed using
PubMed-MEDLINE, Web of Science, and the Cochrane Library
databases. The search was performed without date restriction and
was completed on January 11, 2019. The database searches were
performed independently by 2 different authors (LA and JARA).
The following combination of search terms was used: (“troponin-
I” OR “troponin I” OR “troponin-T” OR “troponin T” OR
“troponin*” OR “cardiac biomarkers”) AND (“marathon” OR
“ultra-race” OR “ultra-distance” OR “ultra-marathon” OR “ultra-
endurance” OR “ultra-distance” OR “endurance”).
2.3. Data extraction and inclusion and exclusion criteria
In this review article, the following inclusion criteria were con-
sidered: (1) studies analyzing the acute effect of foot races on car-
diac damage markers (cTnI and cTnT); and (2) studies analyzing
cardiac damage markers before and after the race. Studies were
excluded if they included (1) populations with pathologies, (2)
case studies, (3) studies where the training or the race was per-
formed on a treadmill, (4) studies written in languages other than
English or Spanish, (5) running events performed intermittently,
and (6) runners who took supplements or medications.
2.4. Study variables
The levels of cTnT and cTnI were the study variables
on which the effects of endurance racing (endurance race
(1020 km), mountain race, half marathon, marathon, ultra-
marathon, or mountain ultramarathon) were analyzed. These
markers are considered to be indicators of acute coronary syn-
drome, and their elevation is usually associated with cardiac
pathologies; however, they are also sensitive to stressful situa-
tions such as endurance races.20,21
2.5. Evaluation of the methodology of the studies selected
(risk of bias)
The methodological quality of the selected studies was assessed
by the quality-assessment tool used for before-after (pre-post) stud-
ies with no control group (National Heart Lung and Blood Insti-
tute),22 which analyzes the following items: (1) study question; (2)
eligibility criteria and study population; (3) representativeness of
study participants from clinical populations of interest; (4) enrol-
ment of all eligible participants; (5) sample size; (6) clear descrip-
tion of the intervention; (7) outcome measures clearly described,
valid, and reliable; (8) blinding of outcome assessors; (9) follow-up
rate; (10) statistical analysis; (11) multiple outcome measures; and
(12) group-level interventions and individual-level outcome efforts.
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risk of bias, an unclear risk of bias, or a high risk of bias. Two
different authors (LA and DJRC) used the previously described
risk-of-bias tool to assess the risk of bias independently.
2.6. Data synthesis and statistical analysis
The meta-analysis and the statistical analysis were conducted
using Review Manager software (Version 5.2; RevMan,
Cochrane Collaboration, Oxford, UK). A random-effects
meta-analysis was conducted to determine the effects of endur-
ance races on cardiac damage markers. The effects of these race
events were expressed as mean differences (MDs) and their 95%
confidence intervals (95%CIs). The heterogeneity between the
studies was evaluated through the I2 statistic, and the between-
study variance was evaluated using the Tau2 (t2).23 The I2 values
of 30%60% represented a moderate level of heterogeneity. In
addition, a t2 value > 1 suggests the presence of substantial sta-
tistical heterogeneity. The Egger’s test was used to assess publi-
cation bias.24 p  0.05 was considered to be statistically
significant.
2.7. Effects of moderator variables: metaregression and
subanalysis
2.7.1. Moderator analysis for dichotomous variables
To explore the heterogeneity among the variance of the
studies, a metaregression of the continuous variables was
applied. Considered as moderating variables were age, body
mass index (BMI), distance covered, time to complete the
race, and speed. The metaregression was analyzed by a
random-effects model using the Jamovi Project (Package for R
(Version 1.0.0; R Development Core Team, Vienna, Austria)).
A restricted maximum residual plausibility method was used
to measure variance between studies (t2).
2.7.2. Subgroup analysis for dichotomous variables
Subgroup analysis was applied using Review Manager soft-
ware, with gender and type of race used as dichotomous/polito-
mous variables that could have an influence on the heterogeneity.
In addition, distance and time were analyzed under a
dichotomous model (establishing the median as the cut-off
point). In each study, the MDs of pre- and post-race, and 24 h
after the race were calculated. Each difference in mean was
pondered using the method of the inverse variance.25
3. Results
3.1. General characteristics of the studies
To measure the impact of running on the level of cTnI, sta-
tistical analysis was performed on 25 studies with 32 groups;
and to measure the level of cTnT, it was performed on 26 stud-
ies with 33 groups (Fig. 1). The mean age of the participants
was 40.4 years (range: 15.763.4 years) in cTnI and 41.1 years
(range: 15.763.0 years) in cTnT. Participants had a mean
BMI of 23.4 § 1.5 kg/m2 (mean § SD) in the cTnI groups and
22.8 § 1.9 kg/m2 in the cTnT groups. The descriptive charac-
teristics and references can be seen in Supplementary Table 1.3.2. Risk of bias and heterogeneity
The score obtained (median) in the risk analysis was 7/9 (Sup-
plementary Table 2). The funnel test showed heterogeneity of
studies (Fig. 2). In addition, a significant bias was observed in the
cTnI (Fig. 2A) for the 32 groups analyzed by using the Egger’s
test (Z = 4.67, p < 0.001). However, the bias was not significant
in the cTnT (Fig. 2B) for the 33 groups analyzed (Z = 1.54,
p = 0.123).
3.3. Meta-analysis
The overall effect of running on cTnI (Fig. 3) was analyzed in
825 runners. The races generated a significant post-race increase
in cTnI levels (MD= 0.0381 ng/mL, 95%CI: 0.03330.0428, p
< 0.001). Likewise, the effect of races on cTnT for 1195 runners
displayed a significant postrace increase (MD= 0.0256 ng/mL,
95%CI: 0.02310.0282, p< 0.001).
3.4. Metaregression results
The results of the metaregression are shown in Table 1 (cTnI)
and Table 2 (cTnT). A negative interaction was observed among
cTnI, age (adjusted R2 = 14.4%; t2 = 0.0022), and BMI (adjusted
R2 = 14.5%; t2 = 0.0018).
3.5. Sub-group results
The overall effect of running on cTnI remained high until
24 h, when the effect on markers became significantly reduced
(x2 = 149.28, p < 0.001). Similarly, the effect of the race on
the cTnT remained high until 24 h); then it showed a signifi-
cant decrease (x2 = 4.21, p = 0.04) (Table 3). In addition,
there was a greater increase in cTnI than in cTnT (x2 = 20.49,
p < 0.001) post-race. However, higher cTnT values were
observed at 24 h (x2 = 4.87, p = 0.03).
3.6. Gender
When studies were grouped by gender (Table 3), the differen-
ces of the increases in the observed cTnI values (x2 = 56.51,
p < 0.001) were higher in the studies involving men and women
(n = 502 participants; MD= 0.071 ng/mL, 95%CI: 0.0580.085,
p < 0.001) and in the studies involving only men (n = 323 par-
ticipants; MD= 0.018 ng/mL, 95%CI: 0.0140.021, p < 0.001).
However, no differences in cTnT values (x2 = 0.01, p = 0.92)
were observed in men or in studies involving men and women.
Only 2 studies (3 groups) that analyzed the effect of endurance
races in women were identified, and when they were added to
the analysis, a significant increase in cTnT was observed
(n = 108 participants; MD= 0.014 ng/mL, 95%CI: 0.0080.020,
p < 0.001). However, this increased response in women was
lower compared to men (x2 = 15.55, p < 0.001) and compared
to studies involving men and women (x2 = 7.75, p = 0.005).
3.7. Type of competition
Significant differences in cTnI were observed depending on the
type of event (x2 = 96.19, p < 0.001) (Table 3). The highest
postcompetition cTnI values were observed for marathon (n= 627;
Fig. 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram of included and excluded studies.
Damage markers and long distance running 195MD=0.062 ng/mL, 95%CI: 0.0550.070, p < 0.001), followed
by the half marathon (n= 87; MD=0.046 ng/mL, 95%CI:
0.0130.078, p= 0.006), and the mountain ultramarathon (n= 34;
MD=0.023 ng/mL, 95%CI: 0.0090.037, p= 0.001). In addition,
when speed and exposure time were analyzed under a dichotomous
model, significant differences were observed in cTnI (Fig. 2), with
higher values for runners running at lower speeds than for those
running at higher speeds (x2 = 14.58, p= 0.0001) and for those
completing the route in a longer time than for those completing it in
a shorter time (x2 = 6.32, p= 0.01) (Table 3).Fig. 2. Assessment of risk of bias for included studies (funnel plot): (A) m4. Discussion
4.1. Persistence over time
The obtained results showed a significant increase in postef-
fort cTns, which remained elevated until 24 h post effort. In
line with this finding, previous studies have indicated that sus-
tained efforts of long duration and intensity generate signifi-
cant and reversible increases in the release of posteffort cTns,
so the effect of cardiac necrosis is not ruled out due to repeated
efforts over time.26,27 A transient increase in the membraneean differences for troponin I and (B) mean differences for troponin T.
Fig. 3. Effects of running races on cardiac damage markers: (A) forest plot for troponin I and (B) forest plot for troponin T. The references of the studies included
in the quantitative analysis are summarized in Supplementary Table 1. CI = confidence interval; G1 = Group 1; G2 = Group 2; G3 = Group 3; G4 = Group 4; G5 =
Group 5; IV = inverse variance; SD = standard deviation.
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Table 1
Metaregression analysis of troponin I.
95%CI 95%CI




p t2 (SE) Adj R2 (%) I2 (%) p
Post-race
No covariable 32 0.058 0.040 0.076 <0.001 — — — — 0.0025 (7e-04) — 100.0 <0.001
Age (year) 30 0.140 0.066 0.214 <0.001 0.002 0.004 0.000 0.033 0.0022 (7e-04) 14.4 99.9 <0.001
BMI (kg/m2) 25 0.351 0.065 0.637 0.016 0.012 0.025 0.000 0.045 0.0018 (6e-04) 14.5 99.7 <0.001
Cumulative
elevation
32 0.061 0.041 0.081 <0.001 0.000 0.000 0.000 0.426 0.0026 (7e-04) 0 100.0 <0.001
Distance (km) 32 0.071 0.045 0.097 <0.001 0.000 0.001 0.000 0.166 0.0024 (7e-04) 4.0 100.0 <0.001
Time (min) 29 0.070 0.047 0.093 <0.001 0.000 0.000 0.000 0.18 0.0026 (8e-04) 2.8 100.0 <0.001
Speed (km/h) 29 0.045 0.057 0.147 0.391 0.002 0.008 0.011 0.716 0.0027 (8e-04) 0 100.0 <0.001
24 h
No covariable 12 0.020 0.000 0.040 0.05 — — — — 0.0012 (5e-04) — 100.0 <0.001
Age (year) 12 0.009 0.054 0.072 0.778 0.000 0.001 0.002 0.719 0.0013 (6e-04) 0 99.9 <0.001
BMI (kg/m2) 11 0.034 0.032 0.101 0.313 0.001 0.004 0.002 0.409 0.0001 (0.0000) 0 99.0 <0.001
Cumulative
elevation
12 0.024 0.001 0.046 0.038 0.000 0.000 0.000 0.394 0.0012 (6e-04) 0 99.9 <0.001
Distance (km) 12 0.039 0.004 0.083 0.078 0.000 0.001 0.000 0.324 0.0012 (6e-04) 0 99.9 <0.001
Time (min) 11 0.030 0.002 0.057 0.034 0.000 0.000 0.000 0.342 0.0013 (7e-04) 0 99.9 <0.001
Speed (km/h) 11 0.000 0.060 0.060 1.000 0.145 0.227 0.516 0.445 0.0014 (7e-04) 0 99.9 <0.001
Abbreviations: Adj. = adjusted; BMI = body mass index; CI = confidence interval; coeff. = coefficient.
Table 2
Metaregression analysis of troponin T.
95%CI 95%CI




p t2 (SE) Adj R2 (%) I2 (%) p
Post-race
No covariable 33 0.026 0.021 0.032 <0.001 — — — — 2e-04 (1e-04) — 99.9 <0.001
Age (year) 29 0.017 0.006 0.039 0.158 0.000 0.000 0.001 0.325 3e-04 (1e-04) 3.8 99.8 <0.001
BMI (kg/m2) 23 0.071 0.162 0.019 0.121 0.004 0.000 0.008 0.036 2e-04 (1e-04) 16.8 99.4 <0.001
Cumulative 33 0.029 0.021 0.037 <0.001 0.000 0.000 0.000 0.305 2e-04 (1e-04) 1.2 99.9 <0.001
Distance (km) 29 0.019 0.006 0.033 0.005 0.000 0.000 0.000 0.197 3e-04 (1e-04) 0.4 99.9 <0.001
Time (min) 29 0.039 0.001 0.077 0.046 0.063 0.264 0.139 0.543 3e-04 (1e-04) 0 99.9 <0.001
24 h <0.001
No covariable 9 0.016 0.003 0.028 0.01 — — — — 3e-04 (2e-04) — 99.9
Age (year) 9 0.003 0.044 0.037 0.87 0.001 0.001 0.002 0.328 3e-04 (2e-04) 0 99.8 <0.001
BMI (kg/m2) 6 0.010 0.212 0.193 0.927 0.001 0.008 0.010 0.817 6e-04 (5e-04) 0 99.8 <0.001
Cumulative elevation 9 0.030 0.009 0.051 0.006 0.000 0.001 0.000 0.126 3e-04 (2e-04) 14.2 99.8 <0.001
Distance (km) 8 0.025 0.003 0.047 0.026 0.000 0.000 0.000 0.234 4e-04 (2e-04) 4.7 99.7 <0.001
Time (min) 8 0.013 0.091 0.064 0.735 0.141 0.245 0.528 0.473 4e-04 (3e-04) 0 99.8 <0.001
Abbreviations: Adj. = adjusted; BMI = body mass index; CI = confidence interval; coeff. = coefficient.
Damage markers and long distance running 197permeability has been proposed as an alternative hypothesis to
necrosis.28 However, the effect of continuous exposure to
these markers is not yet known. Our results suggest a greater
sensitivity of the cTnI to the effect of races and higher cTnT
levels over time, with a reversible effect.
4.2. Age
Regarding the ages of participants, our results revealed a sig-
nificant and negative interaction for age on cTnI (adjusted
R2 = 14.4%), with no interaction on cTnT. This significant nega-
tive interaction is in line with findings in previous studies.29 In a
similar meta-analysis,26 the authors did not find any relationship
between the release of cTnT and the ages and genders of partici-
pants, which is in agreement with the results obtained in our
study. However, Fortescue et al.30 observed that troponin values
were higher in younger and less well-trained runners. The ath-
letes included in the meta-analysis had a mean age of 40.4 years,
ranging between 15.7 years and 63.4 years for cTnI; and of 41.1
years, ranging between 15.7 years and 63.0 years for cTnT, with
a greater number of studies at greater age intervals. One possible
explanation for these results is based on the increase in the car-
diac output and, in addition, the relationship between age and thecardiac remodeling due to exercise. It is known that amateur ath-
letes may suffer from both effects in response to aerobic exer-
cise.3133 These factors could generate less myocardial stress
during acute efforts. Another possible explanation could be the
number of athletic competitions included in the studies. Several
studies suggest that with repeated exercise,30,34 stress-sensitive
muscle fibers can be eliminated through cell necrosis followed
by regeneration. Regeneration of muscle fibers and changes in
connective tissue may protect against exercise-related aggres-
sions and the release of myofibrillary enzymes. If such remodel-
ling occurred in the heart, this conditioning could explain the
tendency of more experienced and older runners to be relatively
less likely to exhibit cTns release.
4.3. BMI
BMI showed a significant and negative interaction with cTnI
(adjusted R2 = 14.5%). However, no interactions were observed
for the total amount of released cTnT. Similarly, Shave et al.26
observed that in long-term events, the amount of released cTnT
was related to body weight. To our knowledge, few studies have
attempted to relate BMI values to the level of released cTns. As
previously shown, anthropometric characteristics are related to
Table 3
Effects of endurance races: subgroup analysis.
Sub-group difference




Pre vs. post 32 825 0.038 (0.033, 0.043) <0.001 100 149.28 <0.001
Pre vs. 24 h 12 246 0.005 (0.003, 0.007) <0.001 95
Gender
Men 19 323 0.018 (0.014, 0.021) <0.001 100 56.51 <0.001
Both men and women 13 502 0.071 (0.058, 0.085) <0.001 95
Type of event
Marathon 18 627 0.062 (0.055, 0.070) <0.001 99 96.19 <0.001
Half marathon 5 87 0.046 (0.013, 0.078) 0.006 100
Ultra-marathon 4 56 0.007 (0.002, 0.016) 0.140 98
Ultra-marathon-mountain 4 34 0.023 (0.009, 0.037) 0.001 81
Speed (km/h)
10.3 15 419 0.067 (0.051, 0.082) <0.001 100 14.58 0.0001
>10.3 16 388 0.034 (0.028, 0.040) <0.001 100
Duration (min)
245 16 435 0.037 (0.031, 0.044) <0.001 100 6.32 0.01
>245 15 372 0.057 (0.043, 0.070) <0.001 100
Troponin T
Time point
Pre vs. post 33 1195 0.003 (0.023, 0.028) <0.001 99 4.21 0.04
Prerace vs. 24 h 9 175 0.002 (0.006, 0.025) <0.001 100
Gender
Men 14 318 0.026 (0.024, 0.028) <0.001 94 15.87 0.0004
Women 3 108 0.014 (0.008, 0.020) <0.001 33
Both men and women 16 769 0.026 (0.020, 0.033) <0.001 100
Type of event
Marathon 17 793 0.027 (0.025, 0.029) <0.001 98 4.42 0.35
Half marathon 6 90 0.021 (0.014, 0.027) <0.001 99
Race 6 248 0.028 (0.011, 0.044) 0.001 100
Race-mountain 2 44 0.013 (0.011, 0.036) 0.300 0
Ultra-marathon 2 20 0.027 (0.025, 0.080) 0.310 86
Speed (km/h)
14 15 571 0.026 (0.023, 0.028) <0.001 98 0.32 0.57
14 16 459 0.029 (0.019, 0.038) <0.001 100
Duration (min)
215 15 380 0.024 (0.014, 0.034) <0.001 100 0.55 046
>216 16 650 0.028 (0.026, 0.030) <0.001 98
Notes: In these analyses, not all studies show all variables. Therefore, some variables are calculated with fewer studies (groups).
Abbreviation: CI = confidence interval.
198 J.A. Rubio-Arias et al.aerobic performance in endurance runners.35 Therefore, this asso-
ciation could be due to the fact that BMI is associated with weight.
Moreover, in amateur athletes, the BMI value is associated with a
higher percentage of fat mass, which could be related to a lower
running speed, leading to a lower intensity of effort during the
race and resulting in a lower myocardial effort.4.4. Gender
A significant interaction was shown between 2 subgroups in
the studies that included men only and those that included both
men and women. For cTnT, only 2 studies analyzed the effect
of endurance races for women,36,37 where the cTnT released in
women was lower than that in men. These results are consis-
tent with previous studies showing that cardiac function in
exertion depends on several factors, for example, gender.38
A putative explanation for these results could be that a lower
diastolic capacity is related to a poorer sports performance, and
other factors, such as age and gender, may be related to lower
systolic capacity.39 The difference in ventricular capacity may
lead to a decrease in ventricular stress and, therefore, less heart
damage. Another explanation for the differences related to gen-
der could be the differing estrogen levels in men and womenwhich, in this case, act as a protector of the myocardium.40 Yet
another explanation may be the difference in heart size; it is
known that after puberty, there are differences in heart size
between the genders.37,41 In addition, healthy women show bet-
ter diastolic and systolic function compared to men of the same
age,42 which may be conditioning the effect on stress during
exercise. It has also been shown that coping strategies may
weaken with age, depending on gender.39
However, cTnI values in men were significantly lower than
in combined groups of men and women. This inconsistency
with previous results could be explained by the fact that men’s
groups completed races of an average duration of 929 min
(range: 803758 min), whereas groups consisting of both gen-
ders completed races of an average duration of 205 min (range:
58293 min), with an average race distance of 69.2 km (range:
21.1308.0 km) for men and 33.9 km (range: 10.042.2 km)
for women. Therefore, the intensities at which the events took
place were higher, which may affect the results.434.5. Distance, intensity, and type of event
According to the metaregression, our results revealed that
there is no interaction between the total level of released cTns
Damage markers and long distance running 199and the distance, time, and speed variables. However, when the
cTnI levels were analyzed as a function of the cut-off point
(median), a significant interaction was observed between veloc-
ity and time. Participants who covered longer distances (who,
therefore, had more time of exposure to effort) had greater and
significant increases (x2 = 6.32, p = 0.01) than did those who
were exposed for less time (and who, therefore, covered shorter
distances). In addition, when analyzing the types of events, we
observed that intensity was a key factor in the release of cTnI.
The runners who covered the marathon distance released the
largest amounts of cTnI, followed by those who completed the
half marathon. In addition, nonsignificant differences for the
endurance race (1020 km) and the ultramarathon were found,
and significant differences were reported for the ultramarathon-
mountain. These results suggest that a minimum time of high-
intensity exposure is necessary to generate a significant release
of cTnI. If the race is not long enough (half-marathon dis-
tance)15 or is not performed at a certain intensity, no significant
levels of cTns will be generated. Our results are consistent with
the results previously found in other studies.15,43,44
Legaz-Arrese et al.45 observed that a certain intensity must
be maintained over a certain period of time to generate a sig-
nificant release of cTnI, indicating that the specific release
kinetics are not known to be exponential. This fact coincides
with the cardiac adaptations that could be produced in the long
term and be harmful to health.46
One of the limitations of our analysis is that it did not con-
sider the methods of obtaining the cTns levels (due to missing
information in the articles), and there could have been a loss in
the sensitivity when obtaining the preanalysis values.47
Another limitation is that there was little information available
in the included studies that mentioned the athletes’ experience,
and runners’ experience is one of the limiting factors for the
determination of the cTns levels.48 However, the level of the
participants’ experience identified in the studies included in
our analysis was too vague to establish it as a categorical factor
in our analysis. In addition, the collection time for blood sam-
ples was immediately after the race in many of the analyzed
studies, and it has been observed that the cTns level peaks at
approximately 4 h following a race.21 Finally, it is important
to highlight the fact that an elevated degree of heterogeneity
was shown in the analysis, which was probably due to the fac-
tors mentioned above.5. Conclusion
A few studies have shown the effect of endurance running on
cardiac damage markers. It is known that there can be an interac-
tion between a study population’s characteristics and a running
event’s characteristics on the measured cTns levels, but thus far,
relevant studies have been limited and have had small sample
sizes.
To our knowledge, this is the first meta-analysis that ana-
lyzed the effects of foot races and the factors that generate
greater cTns release in amateur athletes. The main findings in
our analysis were that endurance races generate an increase of
cTnI and cTnT releases, which remain at high levels for atleast 24 h. In addition, several moderating variables that affect
cTns levels after long-distance running were identified.
Endurance foot races generate increased markers of heart
damage and persist at high levels for a minimum of 24 h after-
ward. Gender, duration of effort, speed, and type of race are
moderating factors related to levels of cTnI release.
It is recommended that runners be adequately prepared for
certain types of competitions, especially those that combine
long duration and moderate intensity (i.e., marathons). This is
true especially for men and inexperienced or young partici-
pants who have high fat percentages or high BMIs.
As a clinical application, previous studies suggest that cau-
tion should be taken with those people who show high values
in cardiac damage markers after running49 because these
markers could be the result of exposure to vigorous exercise.
Amateur runners who have these characteristics should be
warned about the risk of performing aerobic events at vigorous
intensity. In addition, it has been observed that cTnI is more
responsive to the effect of certain moderating variables; this may
be because it is a more sensitive marker in relation to the effects
of running. However, this difference could be due to the lack of
initial heterogeneity of the cTnT results. Finally, we must point
out that our message is not about running being harmful to health
but, rather, that the acute effects caused by endurance races with
certain features may increase in people with certain characteris-
tics. From a clinical point of view, this information is relevant for
health care professionals because it provides information about
how an acute situation can be exacerbated when the aforemen-
tioned characteristics are present. For this reason, it is recom-
mended that runners be adequately trained and prepared in order
to fully benefit from the positive effects of PA and to minimize
the acute effects of running.Acknowledgment
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